New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:38 EDTACT, MS, FRX, GSMorgan Stanley, Goldman said to switch fees for deal credit, Bloomberg says
Morgan Stanley (MS) and Goldman Sachs (GS) both decided last month that it was worth losing millions of dollars in fees to get credit on the $25B sale of Forest Laboratories (FRX) to Actavis (ACT), according to Bloomberg, citing four people with knowledge of the matter. The sources say that neither investment bank actually had a role on the deal. Reference Link
News For MS;GS;FRX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 22, 2015
07:00 EDTGSGoldman Sachs making major investments despite Volcker Rule, NY Times says
Goldman Sachs has been making significant investments with its own money despite the Volcker Rule ,which many had assumed would prevent such deals, according to The New York Times. Goldman has managed to find ways to make major deals with its own funds without appearing to violate the law, even as its competitors avoid such transactions, the newspaper stated. Reference Link
06:13 EDTGSGoldman Sachs to lead $56M investment in Antuit Holdings, WSJ reports
Subscribe for More Information
05:57 EDTACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTACTGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:50 EDTMSMorgan Stanley's deferment of bonuses lowered to 50%, NY Post says
Subscribe for More Information
07:22 EDTACTActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
16:23 EDTMSOn The Fly: Closing Wrap
Stocks began the session in positive territory, but the major averages were unable to hold their early gains. Lackluster earnings reports, the falling price of oil, and lowered global growth expectations appeared to be too much to overcome after a three day holiday weekend. The Dow led the way lower and had losses of more than 100 points before reversing and slowly paring its losses. Late in the day the averages made it back to positive ground, as investors await the next round of earnings due out after the close. ECONOMIC EVENTS: In the U.S., the NAHB homebuilder sentiment index fell to 57 in January, missing expectations for it to hold steady at 58. In China, Q4 GDP growth of 7.3% came in slightly better than expected, though that puts the nation's 2014 GDP growth at 7.4%, which was the lowest reported in 24 years. Of note, the International Monetary Fund cut its forecast for global growth in 2015 to 3.5% and in 2016 to 3.7%, which were both revised down by 0.3% relative to the organization's October 2014 outlook. COMPANY NEWS: Shares of Johnson & Johnson (JNJ) led all decliners on the Dow Jones Industrial Average with a drop of $2.75, or 2.64%, to $101.29 after its Q4 earnings were nearly in-line and its FY15 outlook failed to spur buying of the stock... Morgan Stanley (MS) declined 14c, or 0.4%, to $34.75 after the firm became the latest in the financial space to report headline earnings that missed expectations. MAJOR MOVERS: Among the notable gainers was Smith & Wesson (SWHC), which rose $1.65, or 16.47%, to $11.67 after the gunmaker increased its financial guidance and said it has seen recent, positive trends in the primary indicators it uses to assess its business and the consumer firearm market. Also higher was Orbitz Worldwide (OWW), which jumped 79c, or 8.62%, to $9.95 after Bloomberg reported that the online travel agency is working with an adviser to contact potential buyers and has drawn interest from private-equity funds and "other Internet companies." Among the noteworthy losers was FXCM (FXCM), which plunged $11.03, or 87.33%, to $1.60 after the stock reopened following the company struck a $300M rescue agreement with Leucadia (LUK) and gave further details on that deal over the weekend. Also lower were shares of Redbox owner Outerwall (OUTR), which fell $15.72, or 20.21%, to $62.05 after the company announced that its CEO had stepped down. INDEXES: The Dow rose 3.66, or 0.02%, to 17,515.23, the Nasdaq gained 20.46, or 0.44%, to 4,654.85, and the S&P 500 advanced 3.13, or 0.15%, to 2,022.55.
13:08 EDTMSOn The Fly: Midday Wrap
Subscribe for More Information
10:58 EDTMSMorgan Stanley reports 6.1% passive stake in Madison Square Garden
09:14 EDTMSMorgan Stanley does not see lower oil hurting physical oil business sale process
Subscribe for More Information
09:11 EDTMSOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTMSMorgan Stanley says still committed to sale of oil and gas commodities business
08:50 EDTMSMorgan Stanley sees 'clear path' to ROE of 10%
Morgan Stanley sees driving ROE above 10% in Fixed Income and Commodities. On reduction and optimization of Risk-Weighted Assets in Fixed Income and Commodities, the firm said it is on track to achieve year end 2015 target of below $180B and sees additional capital opportunity through passive roll-down of $25B of RWAs by year-end 2018. Morgan Stanley sees a "meaningful reduction" in funding costs due to spread tightening and roll-off of older more expensive debt. For target Compensation/Net Revenue ratios, Morgan Stanley sees Institutional Securities 39% in 2015 in a flat revenue environment; sees Wealth Management 55% over time in a flat interest rate environment; and sees Investment Management 40% over time. Morgan Stanley intends to continue to increase its capital return to shareholders over time, subject to regulatory approval, the company noted. Comments and guidance from Q4 earnings conference call and slides.
07:28 EDTGSTreasury Institute for Higher Education to hold a symposium
Subscribe for More Information
07:08 EDTMSMorgan Stanley says Q4 affected by 'choppy market conditions'
Subscribe for More Information
07:07 EDTMSMorgan Stanley reports Q4 book value of $34.62
Subscribe for More Information
07:07 EDTMSMorgan Stanley Common Equity Tier 1 risk-based capital ratio 14.2%
Subscribe for More Information
07:05 EDTMSMorgan Stanley reports Q4 continuing ops EPS 47c, consensus 48c
Subscribe for More Information
07:02 EDTMSMorgan Stanley reports Q4 EPS ex-DVA 40c, consensus 48c
Subscribe for More Information
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use